Bacterial meningitis early management: Difference between revisions
Jump to navigation
Jump to search
/* EFNS guideline on the Pathogen Specific Antibiotic Therapy in Suspected ABM: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.{{cite journal| author=Chaudhuri A, Martinez-Martin P, Martin PM, Kennedy PG, A... |
/* EFNS guideline on the Pathogen Specific Antibiotic Therapy in Suspected ABM: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.{{cite journal| author=Chaudhuri A, Martinez-Martin P, Martin PM, Kennedy PG, A... |
||
Line 39: | Line 39: | ||
* [[Ampicillin]]/[[Amoxicillin]] 2 g 4 hourly if [[Listeria]] is suspected [IVA] | * [[Ampicillin]]/[[Amoxicillin]] 2 g 4 hourly if [[Listeria]] is suspected [IVA] | ||
}} | |||
==EFNS guideline on the Pathogen Specific Antibiotic Therapy in Suspected ABM: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.<ref name="pmid18582342">{{cite journal| author=Chaudhuri A, Martinez-Martin P, Martin PM, Kennedy PG, Andrew Seaton R, Portegies P et al.| title=EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. | journal=Eur J Neurol | year= 2008 | volume= 15 | issue= 7 | pages= 649-59 | pmid=18582342 | doi=10.1111/j.1468-1331.2008.02193.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18582342 }} </ref> (DO NOT EDIT)== | |||
{{lquote| | |||
===Pathogen Specific Antibiotic Therapy in Suspected ABM=== | |||
====Pneumococcal meningitis==== | |||
* Penicillin-sensitive [[Pneumococcal]] [[meningitis]] (and including other sensitive Streptococcal species): Benzyl [[Penicillin]] 250,000 Units/kg/day (equivalent to 2.4 g 4 hourly) [IVA] or [[Ampicillin]]/[[Amoxicillin]] 2 g 4 hourly or [[Ceftriaxone]] 2 g 12 hourly or [[Cefotaxime]] 2 g 6 to 8 hourly. | |||
* Alternative therapy: [[Meropenem]] 2 g 8 hourly [IVC] or [[Vancomycin]] 60 mg/kg 24 hourly as continuous infusion (adjusted for [[creatinine clearance]]) '''after 15 mg/kg loading dose aiming for serum levels of 15 to 25 mg/l''') plus [[Rifampicin]] 600 mg 12 hourly [IVC] or, [[Moxifloxacin]] 400 mg daily [IVC] | |||
* [[Pneumococcus]] with reduced susceptibility to [[penicillin]] or [[cephalosporins]]: [[Ceftriaxone]] or [[Cefotaxime]] plus [[Vancomycin]] ± [[Rifampicin]] [IV]. Alternative therapy: [[Moxifloxacin]], [[Meropenem]] or [[Linezolid]] 600 mg combined with [[Rifampicin]] [IV] | |||
====Meningococcal meningitis==== | |||
* [[Meningococcal meningitis]]: Benzyl Penicillin or Ceftriaxone or Cefotaxime [IV]. | |||
* Alternative therapy: [[Meropenem]] or [[Chloramphenicol]] or [[Moxifloxacin]] [IVC] | |||
====Haemophilus influenzae type B (Hib)==== | |||
* Haemophilus influenzae type B (Hib): [[Ceftriaxone]] or [[Cefotaxime]] [IVC]. | |||
* Alternative therapy: IV Chloramphenicol–Ampicillin/ [[Amoxicillin]] [IVC] | |||
====Listerial meningitis==== | |||
* Listerial meningitis: [[Ampicillin]] or [[Amoxicillin]] 2 g 4 hourly ± [[Gentamicin]] 1 to 2 mg 8 hourly for the first 7 to 10 days [IVC]. | |||
* Alternative therapy: [[Trimethoprim]]–[[Sulfamethoxazole]] 10 to 20 mg/kg 6 to 12 hourly or Meropenem [IV] | |||
====Staphylococcal species==== | |||
* Staphylococcal species: [[Flucloxacillin]] 2 g 4 hourly [IV] or [[Vancomycin]] if penicillin allergy is suspected [IV]. | |||
* Rifampicin should also be considered in addition to either agent, and Linezolid for methicillin-resistant staphylococcal meningitis [IVC]. | |||
====Gram-negative Enterobacteriaceae==== | |||
* Gram-negative Enterobacteriaceae: [[Ceftriaxone]] or [[Cefotaxime]] or [[Meropenem]] | |||
====Pseudomonal meningitis==== | |||
* Pseudomonal meningitis: [[Meropenem]] ± [[Gentamicin]] | |||
}} | }} | ||
Revision as of 16:28, 30 September 2012
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.[1] (DO NOT EDIT)
“ |
Early Management of Acute Bacterial Meningitis (ABM)
|
” |
EFNS guideline on the Empirical Antibiotic Therapy in Suspected ABM of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.[1] (DO NOT EDIT)
“ |
Specific Antibiotic Treatment
Empirical Antibiotic Therapy in Suspected ABM
|
” |
EFNS guideline on the Pathogen Specific Antibiotic Therapy in Suspected ABM: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.[1] (DO NOT EDIT)
“ |
Pathogen Specific Antibiotic Therapy in Suspected ABMPneumococcal meningitis
Meningococcal meningitis
Haemophilus influenzae type B (Hib)
Listerial meningitis
Staphylococcal species
Gram-negative Enterobacteriaceae
Pseudomonal meningitis
|
” |
EFNS guideline on the Pathogen Specific Antibiotic Therapy in Suspected ABM: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.[1] (DO NOT EDIT)
“ |
Pathogen Specific Antibiotic Therapy in Suspected ABMPneumococcal meningitis
Meningococcal meningitis
Haemophilus influenzae type B (Hib)
Listerial meningitis
Staphylococcal species
Gram-negative Enterobacteriaceae
Pseudomonal meningitis
|
” |
References
- ↑ 1.0 1.1 1.2 1.3 Chaudhuri A, Martinez-Martin P, Martin PM, Kennedy PG, Andrew Seaton R, Portegies P; et al. (2008). "EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults". Eur J Neurol. 15 (7): 649–59. doi:10.1111/j.1468-1331.2008.02193.x. PMID 18582342.